Better Therapeutics (OTCPK:BTTX) - Stock Price, News & Analysis

BTTX Stock Overview

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases.

About the company

BTTX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Revenue is forecast to grow 256.37% per year

Risk Analysis

Negative shareholders equity

Earnings are forecast to decline by an average of 40.6% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

+ 3 more risks

Better Therapeutics, Inc. Competitors

SCWorx

NasdaqCM:WORX

US$2.8m

iSpecimen

NasdaqCM:ISPC

US$2.5m

SOAFEE

OTCPK:SOFE

US$98.7k

TRxADE HEALTH

NasdaqCM:MEDS

US$8.9m

Price History & Performance

Summary of all time highs, changes and price drops for Better Therapeutics
Historical stock prices
Current Share Price	US$0.01
52 Week High	US$1.35
52 Week Low	US$0.005
Beta	2.13
1 Month Change	-22.48%
3 Month Change	-94.64%
1 Year Change	-99.14%
3 Year Change	-99.90%
5 Year Change	n/a
Change since IPO	n/a

Recent updates

Better Therapeutics files for FDA approval of new type of digital therapy for diabetes

Sep 22

Better Therapeutics GAAP EPS of -$0.42 in-line

Aug 11

Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel

May 12

Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases

Nov 30

Shareholder Returns

	BTTX	US Healthcare Services	US Market
7D	61.3%	-0.8%	1.0%
1Y	-99.1%	-9.6%	21.9%

Return vs Industry: BTTX underperformed the US Healthcare Services industry which returned -9.6% over the past year.

Return vs Market: BTTX underperformed the US Market which returned 21.9% over the past year.

Price Volatility

Is BTTX's price volatile compared to industry and market?
BTTX volatility
BTTX Average Weekly Movement	41.8%
Healthcare Services Industry Average Movement	9.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Stable Share Price: BTTX's share price has been volatile over the past 3 months.

Volatility Over Time: BTTX's weekly volatility has increased from 25% to 42% over the past year.

About the Company

Founded	Employees	CEO	Website
2015	54	Frank Karbe	www.bettertx.com

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions.

Better Therapeutics, Inc. Fundamentals Summary

How do Better Therapeutics's earnings and revenue compare to its market cap?
BTTX fundamental statistics
Market cap	US$545.16k
Earnings (TTM)	-US$31.57m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is BTTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BTTX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$31.57m
Earnings	-US$31.57m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.58
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-144.0%

How did BTTX perform over the long term?

See historical performance and comparison

BTTX Stock Overview

Rewards

Risk Analysis

Better Therapeutics, Inc. Competitors

NasdaqCM:WORX

US$2.8m

NasdaqCM:ISPC

US$2.5m

OTCPK:SOFE

US$98.7k

NasdaqCM:MEDS

US$8.9m

Price History & Performance

Recent News & Updates

Better Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price and Market Value of Listed Securities Requirements for Continued Listing on The Nasdaq Capital Market

Better Therapeutics Voluntarily Requests a Delisting of its Securities and Expects its Securities to Be Delisted in the Near Term

Better Therapeutics Voluntarily Requests a Delisting of its Securities and Expects its Securities to Be Delisted in the Near Term

Better Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

Better Therapeutics, Inc. announced that it has received $0.25 million in funding

Recent updates

Better Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price and Market Value of Listed Securities Requirements for Continued Listing on The Nasdaq Capital Market

Better Therapeutics Voluntarily Requests a Delisting of its Securities and Expects its Securities to Be Delisted in the Near Term

Better Therapeutics Voluntarily Requests a Delisting of its Securities and Expects its Securities to Be Delisted in the Near Term

Better Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

Better Therapeutics, Inc. announced that it has received $0.25 million in funding

Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone

Better Therapeutics, Inc. Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

Better Therapeutics Provides Non-Compliance Update

New major risk - Share price stability

Better Therapeutics, Inc. Announces CFO Changes, Effective November 27, 2023

Better Therapeutics, Inc. Announces CFO Changes, Effective November 27, 2023

New major risk - Financial position

Better Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Revenue and earnings growth

New major risk - Market cap size

Better Therapeutics, Inc. Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes

Better Therapeutics, Inc. Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes

Better Therapeutics, Inc. announced that it has received $2.115287 million in funding

Price target decreased by 20% to US$6.00

Better Therapeutics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Shareholder dilution

Better Therapeutics, Inc. announced that it expects to receive $2.115287 million in funding

Better Therapeutics, Inc. announced that it expects to receive $2.115287 million in funding

Better Therapeutics, Inc. Receives Fda Authorization for Aspyrerx to Treat Adults with Type 2 Diabetes

Better Therapeutics, Inc. Receives Fda Authorization for Aspyrerx to Treat Adults with Type 2 Diabetes

Better Therapeutics, Inc. Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates increase by 33%, EPS downgraded

Better Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 34% to US$11.67

Better Therapeutics, Inc. Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results

High number of new and inexperienced directors

Better Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer

Better Therapeutics, Inc. Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 Diabetes

Better Therapeutics files for FDA approval of new type of digital therapy for diabetes

Head of Finance & Interim CFO recently bought US$97k worth of stock

Better Therapeutics GAAP EPS of -$0.42 in-line

Better Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Better Therapeutics, Inc. Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results

Better Therapeutics, Inc. Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001

Better Therapeutics, Inc. Appoints Frank Karbe as President and as Member of the Board of Directors Starting July 5, 2022

Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel

Better Therapeutics, Inc. to Report Q1, 2022 Results on May 13, 2022

High number of new and inexperienced directors

Independent Director recently bought US$86k worth of stock

Better Therapeutics, Inc. Announces Positive Primary Endpoint Data from the Pivotal Clinical Trial for the company's BT-001 Prescription Digital Therapeutic

Better Therapeutics, Inc. Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapies

Better Therapeutics, Inc. Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research

Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases

Less than half of directors are independent

Shareholder Returns

Price Volatility

About the Company

Better Therapeutics, Inc. Fundamentals Summary

0.0x

0.0x

Earnings & Revenue